In this episode of the Psychedelic Spotlight podcast, we catch up with Ronan Levy, Co-Founder and Executive Chairman of Field Trip Health.
Similar Posts
Psychedelic Business Roundup- Key Psychedelic Industry Leader Joins The NASDAQ
May 12, 2021- This week’s Psychedelic Business News Round Up’s…
Psychedelic Spotlight Interview with Daniel Carcillo
In this episode of the Psychedelic Spotlight podcast, we catch…
Curing Alcoholism with Ketamine Therapy? | Interview with Psychedelic Scientist Dr. Ben Sessa -Awakn
In today’s episode of The Psychedelic Investor, James Hallifax interviews Dr. Ben Sessa of Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a psychedelic medicines company.
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Dr. Ben Sessa is the Chief Medical Officer of Awakn and a well-known scientist in the psychedelics field.
In this conversation, Awakn’s newest clinical trial is discussed. The phase 2 trial treated Alcohol Use Disorder using ketamine-assisted therapy, and the results were amazing. For example, by the end of the trial, 86% of participants remained abstinent from alcohol.
From this trial, it is clear that psychedelic therapy, or in this case ketamine therapy, can help with treating addiction. Perhaps the implications of the study go further.
Perhaps, psychedelics can treat mental health issues in general.
Perhaps, ketamine can be used to heal.
In the conversation, MDMA to treat addiction was also discussed.
Interestingly, Dr. Ben Sessa may be the only person in the world who has LEGALLY taken MDMA, psilocybin, LSD and Ketamine.
With mental health care in the spotlight, and we so obviously have a mental health crisis, psychedelic medicines are seeming more likely to be the answer.
From an investment perspective, psychedelic stocks are looking like they could be the next big thing. While there is no guarantee that Awakn will ultimately be a winner, their psychedelic research is definitely a boon for all psychedelic stocks.
#Psychedelics #Awakn #PsychedelicStocks
Interview With Henri Sant-Cassia, The Conscious Fund
Global Trac Solutions, Inc. CEO, David Flores sits down to speak with Co-Founding Partner at The Conscious Fund, Henri Sant-Cassia.
Can Ketamine Therapy Be the Solution for Treatment Resistant Depression & Opioid Addiction?
Ketamine therapy is shaping up to be one of the…
How Long Until Psychedelic Stocks Payoff?🍄🚀| MindMed (MNMD), Cybin (CYBN), Numinus (NUMI) and more
How long until Psychedelic Stocks Payoff?🍄🚀
To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
While researching a possible investment into psychedelic stocks, you have almost certainly heard the refrain of, “It’s a long-term investment.” I myself, in my many videos for The Psychedelic Investor and articles for PsychedelicSpotlight.com, have probably said this over 100 times.
And while the thesis for investing in psychedelic stocks is appealing, having a timeline clearer than “it’s a long term investment” is necessary before deciding whether it is worth the risk.
In this video, therefore, I endeavor to answer a big question: “When will psychedelic stocks provide a significant return on investment?”
Or, translated to Reddit-speak: when moon?
To start, I feel it’s necessary to give the warning that the answer may be never. To be clear, while I personally believe in the potential for psychedelic stocks such as MindMed (Nasdaq: MNMD, NEO: MMED) and Cybin (NYSE: CYBN, NEO: CYBN), the entire psychedelic medicines industry is inherently speculative and there is no guarantee of success. Yes, the science right now suggests that treatments such as MDMA therapy for PTSD and Ketamine therapy for addiction will disrupt the mental healthcare market, but this needs to be confirmed in larger studies.
There will be two separate turning points for psychedelic medicines and the companies that produce them: the legalization of the first psychedelic medicines, and the legalization of improved next-generation psychedelics.
The first will happen relatively soon.
#PsychedelicStocks #MindMed #Cybin